Skip to main content

Foundation Medicine, Roche, Dian Diagnostics Collaborate to Bring Cancer Profiling Tests to China

NEW YORK (GenomeWeb) – Foundation Medicine, Roche, and Dian Diagnostics late on Thursday said they plan to collaborate to offer Foundation’s next-generation sequencing tumor profiling tests to patients in China.

Dian, a China-based medical diagnostic product developer, will be the exclusive clinical sequencing partner in China for Foundation’s tests — FoundationOne, FoundationOne Heme, and FoundationAct. Roche will continue to have commercial exclusivity for Foundation’s molecular information products in China and will work with Dian to support the integration of the assays into clinical care.

Dian holds an NGS pilot license for cancer diagnostics from the National Health Commission of China, and has a network of more than 30 laboratories across mainland China, processing more than 100,000 clinical samples per day.

Dian’s “broad healthcare network will enable [cancer genome profiling] as a critical component of patient care in China,” Melanie Nallicheri, Foundation’s chief business officer and head of biopharma, said in a statement.

“Healthcare is transforming at a rapid pace in China and there is a national urgency to develop strategies that can advance personalized medicine to improve clinical outcomes for patients,” Haibin Chan, chairman of Dian Diagnostics, added.

Financial and other terms of the deal were not disclosed.